Replies to post #412859 on Amarin Corp Plc (AMRN)

[Number sleven]

Kiwi, I understand that this is your humble opinion. That said this is the strategy that Amarin has currently decided on. The reduced wholesale price was a decision made by the company. Laying off employees was also a corporate decision. I agree with Mr. Rockefeller. It looks like Amarin does as well.
Sleven,

[Jvee]

@Whal "Why waste your time selling brand V in the US for $81.65 a mth ( Capts data ) when you can sell it for around $124 a mth ( from memory ...Capts data ) in the UK."

Are you suggesting Amarin should throw in the towel and give up its $65M quarterly sales in the US?

[ziploc_1]

KIWI...QUOTE..."They can afford to run their generic V as a loss leader ...until AMRN drops out of the US market ."

Generic companies are not doing so well lately. Therefore...

-Generic companies will be hesitant to sell large volumes of gV at a loss to them.
-Vascepa will not drop out of the US market...It will, in any event, be taken over by a BP, which will continue it on a global scale...with new EPA configurations and new EPA products, as previously discussed.

Vascepa is not going away..although Amarin will eventuall be bot by a BP